7 Undervalued Biotechnology & Medical Research Stocks for Monday, February 27
Discover the top 7 undervalued Biotechnology & Medical Research stocks for Monday, February 27 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement
with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Commentary & Analysis
5 Undervalued Biotechnology & Medical Research Stocks for Wednesday, January 11
Discover the top 5 undervalued Biotechnology & Medical Research stocks for Wednesday, January 11 based on AAII’s Stock Grades.Jenna Brashear
Is Tempest Therapeutics Stock (TPST) a Good Investment?
Learn more about Tempest Therapeutics Inc’s (TPST) stock grades for Value, Momentum and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Dylan Dease
Is Tempest Therapeutics Stock (TPST) a Good Investment?
Learn more about Tempest Therapeutics Inc’s (TPST) stock grades for Growth, Momentum and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Dylan Dease
Financial Summary
| Share Statistics | TPST | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8.5 | $229.7 | 7% |
|
| Shares Out (Mil) | 15.2 | 53.4 | 26% |
|
| Institutional Ownership | 20.6% | 92.9% | 10% |
|
| Float (Mil) | 11.5 | 41.7 | 21% |
|
| Beta | -1.68 | 0.95 | 0% |
|
| Avg Daily Volume (000s) | 166 | 520 | 43% |
|
| Price Change (52-week) |
(95.0%) | 46.5% | 3% |
|
| Growth | TPST | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (6.5%) | (10.1%) | 32% |
|
| EPS (5yr) | 58.8% | 15.8% | 95 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.0%) | (15.7%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.320) | ($2.850) | ($0.900) | |
| Month Ago EPS | ($0.350) | ($1.340) | ($1.210) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.350) | ($1.340) | ($1.210) | |
| Year/Year Chg | (7.0%) | (55.0%) | na | |
| Financials | TPST | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($41) | ($44) | 18% |
|
| EPS (TTM) | ($4.556) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($21) | ($33) | 15% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $6 | $4 | 26% |
|
| Enterprise Value (Q1) (Mil) | $23 | $175 | 12% |
|
| Valuation | TPST | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.17 | na |
|
| P/E | na | 20.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TPST | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (237.3%) | (47.2%) | 2% |
|
| ROE | (931.1%) | (53.5%) | 0% |
|
| Liabilities to Assets | 111.3% | 29.4% | 96% |
|
| F-Score | 1 | 2 | 1% |
|
Tempest Therapeutics, Inc. did not pass any screens on 10/23/2026.
